Prophylaxis and treatment of CMV infections in transplantation

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 117-134

  Zaia, John A ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CYTOMEGALOVIRUS; INTRAVENOUS DRUG ADMINISTRATION; LUNG LAVAGE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS DETECTION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0029915599     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_13     Document Type: Conference Paper

References (72)

1. Zaia JA. Epidemiology and Pathogenesis of Cytomegalovirus Disease. Semin Hematol 1990;27:5-10.
2. Ho M. Cytomegalovirus: Biology and Infection. Second ed. New York: Plenum; 1991.
3. Meyers JD, Flournoy N, Thomas ED. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplantation. J Infect Dis 1980;142:816-824.
4. Grundy JE, Lui SF, Super M et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus Lancet 1988;ii:132-135.
5. Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus - seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78:246-250.
6. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986,153:478-488.
7. Rubin RH. Infection in the renal and liver transplant patient. Clinical approach to infection in the compromised host, Second Edition. Rubin RH, Young LS, ed New York: Plenum; 1988. p. 53.
8. Rook AH, Quinnan GV, Frederick WJR et al. Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med 1984;76:385-392.
9. Quinnan GV, Kirmani N, Rook AH et al. Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T lymphocyte and non-T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus in bone marrow recipients. N Engl J Med 1982;307: 7-13.
10. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991;78:1373-1380.
11. Boland GJ, Hene RJ, Ververs C, DeHaan MAM/DeGase GC Factors influencing the occurrence of active cytomegalovirus (CMV) infections after organ transplantation. Clin Exp Immunol 1993;94:306-312.
12. Meyers JD, Fluornoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation. A review often years' experience. Rev Infect Dis 1982;4:1119-1132.
13. Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russel PS, Hirsch MS. Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 1977;24:458-464.
14. Betts RF, Freeman RB, Douglas Jr. RG et al. Clinical manifestations of renal allograft derived primary cytomegalovirus infection. Am J Dis Child 1982;131:759-763.
15. Duncan SR, Paradis IL, Yousem SA, et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992;146:1419-1425.
16. Gorensek MJ, Stewart RW, Keys TF, McHenry MC, Goormastic M. A multivariate analysis of the risk of cytomegalovirus infection in heart transplant recipients. J Infect Dis 1988;157:515-522.
17. Dunn DL; Gillingham KJ; Kramer MA et al. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis for cytomegalovirus infection after solid organ transplantation. Transplantation 1994; 57:876-884.
18. Schmidt GM, Horak DA, Niland JC et al. A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991;324:1005-1011.
19. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand? Blood 1994;83:2392-2398.
20. Pecego R, Hill R, Appelbaum FR et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1986;42:515-517.
21. Valteau D, Harmann O, Benhamou E et al. Nonbacterial, nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without totalbody irradiation. Transplantation 1988;45:737-740.
22. Ljungman P, Biron P, Bosi A et al. Cytomegalovirus interstitial pneumonia in autologous bone marrow transplant recipients. Bone Marrow Transplantation. 1994;13:209-212.
23. Griffiths RI, Bass EB, Powe NR et al. Factors influencing third party payer costs for allogeneic bone marrow transplant. Bone Marrow Transplant 1993;12:43-48.
24. Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323:705-712.
25. Ackermann JR, LeForce WM, Weinstein S et al. Four-year experience with exclusive use of cytomegalovirus antibody negative donors for CMV-Ab-negative kidney recipients. Transplant Proc. 1988;20 Suppl 1,469-471.
26. Meyers JD, Reed EC, Shepp DH et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 1988;318:70-75.
27. Balfour Jr. HH, Chace BA, Stapleton JT et al. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-1387.
28. Goodrich JM, Mori M, Gleaves CA et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991;325:1601-1607.
29. Stratta RJ, Shaefer MS. Cushing KA et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg. 1992;127:55-64.
30. Legendre C, Ducloux D, Ferroni A, Chkoff N, Geffrier C, Rouzioux C, Kreis H. Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. J Med Virol 1993;Suppl 1:118-122.
31. Saliba F, Eyraud D, Samuel D, David MR, Arulnaden JL, Dussaix E, Mathieu D, Bismuth H. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplant Proc 1993;25:1444-1445.
32. Cole NL, Balfour Jr, HH. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987;6:255-261.
33. Merigan TC, Renlund DB, Keay S et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Eng J Med 1992;326:1182-1186.
34. Cohen AT, O'Grady JG, Sutherland S et al. Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults. J Med Virol. 1993;40:5-9.
35. Nakazato PZ, Burns W, Moore P, Garcia-Kennedy R, Cox K, Esquivel C. Viral prophylaxis in hepatic transplantation preliminary report of a randomized trial of acyclovir and ganciclovir. Transplant Proc. 1993;25:1935-1937.
36. Singh N, Yu VL, Mieles L et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994;120:375-381.
37. Zaia JA, Levin MJ, Leszczynski J, Wright GG, Grady GF. Cytomegalovirus immune globulin. production from selected normal donor blood. Transplantation 1979;27:66-67.
38. Snydman DR, Werner BG, Heinze-Lacey B et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317:1049-1054.
39. Werner BG, Snydman DR, Freeman R et al. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. Transplant Proc 1993;25:1441-1443.
40. Meyers JD, Ljungman P, Fisher LD. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990;162:373-380.
41. Miller WJ, McCullough J, Balfour HH Jr et al. Prevention of cytomegalovirus infection following bone marrow transplantation a randomized trial of blood product screening. Bone Marrow Transplant 1991;7:227-234.
42. Bowden RA, Sayers MH, Cays M, Slichter SJ. The role of blood product filtration in the prevention of transfusion associated cytomegalovirus infection after marrow transplant. Transfusion 1989;29:5205
43. Zaia JA. Cytomegalovirus infection. Forman SJ, Blume KG, Thomas ED Bone Marrow Transplantation Boston: Blackwell Scientific Publications; 1994. p. 376-403.
44. Boland, GH; Vlieger AM, Ververs C, De Gast GC. Evidence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation Clin Exp Immunol. 1992;88:506-511.
45. Li C, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-1979.
46. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343:749-753.
47. Atkinson K, Downs K, Golenia M et al. Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br J Hematol 1991;79:57-62.
48. Yau JC, Dimopoulos MA, Huan SD et al. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. Eur J Haematol 1991;47:371-376.
49. Goodrich JM, Bowden RA, Fisher L et al. Prevention of cytomegalovirus disease after allogeneic marrow transplant by ganciclovir prophylaxis. Ann Intern Med 1993;118:173-178.
50. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993;118:179-184.
51. von Bueltzingsloewen A, Bordigoni P, Witz F et al. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1993;12:197-202.
52. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992;166:473-479.
53. Ruutu P, Ruutu T, Volin L et al. Cytomegalovirus is frequently isolated in bronchoalveolar lavage fluid of bone marrow transplant recipients without pneumonia. Ann Intern Med 1990;112:913-916.
54. Singh N, Yu VL, Mieles L et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994;120:375-381.
55. Gleaves CA, Smith TF, Shuster EA, Pearson GR. Comparison of standard tube and shell vial cell culture techniques for the detection of cytomegalovirus in clinical specimens. J Clin Microbiol 1985;21:217-221.
56. van der Bij W, Torensma R, vanSon WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988;25:17-188.
57. Grefte JMM, van der Gun BTF, Schmolke S et al. Cytomegalovirus antigenemia assay: identification of the viral antigen as the lower matrix protein pp65. J Infect Dis 1992;166:683-684.
58. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992;80:1358-1364.
59. Saltzman RL, Quirk MR, Jordan MC. High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Invest 1992;90:1832-1838.
60. Demmler GJ, Buffone GJ, Schimbor CM, May RA. Detection of cytomegalovirus in urine from newborns by using polymerase chain reaction DNA amplification. J Infect Dis 1988;158:1177-1184.
61. Cassol SA, Poon M, Pal R et al. Primer-mediated enzymatic amplification of cytomegalovirus (CMV) DNA. J Clin Invest 1989;83:1109-1115.
62. Hsia K, Spector DH, Lawrie J, Spector SA. Enzymatic amplification of human cytomegalovirus sequences by polymerase chain reaction. J Clin Microbiol 1989;27:1802-1809.
63. Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993;56:330-334.
64. van den Berg AP, van Son WJ, Haagsma EB et al. Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients. Transplantation. 1993;55:847-851.
65. Einsele H, Ehninger G. Steidle M et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease Lancet 1991;2:1170-1172.
66. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991;77:1104-1110.
67. Jiwa NM, van Gemert GW, Raap AK et al. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes in viremic transplant recipients by the polymerase chain reaction Transplantalion 1989;48:72-76.
68. Boland GJ, de Weger RA, Tilanus MGJ, Ververs C, Bosboom-Kalsbeek K, de Gast GC. Detection of cytomegalovirus (CMV) in gransulaocytes by polymerase chain reaction compared with the CMV antigen test. J Clin Microbiol 1992;30:1763-1767.
69. Ishigaki S, Takeda M, Kura T, Ban N, Saitoh T. Cytomegalovirus DNA in the sera of patients with cytomegalovirus pneumonia. Br J Haematol 1991;79:198-204.
70. Brytting M, Xu W, Wahren B, Sundqvist VA. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 1992;30:1937-1941.
71. Spector SA, Merrill R, Wolf D, Dankner WM. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992;30:2359-2365.
72. Aspin MM, Gallez-Hawkins GM, Giugni TD et al. Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients J Clin Microbiol 1994;32:2266-2269.